1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two...

por Ramgopal, Moti, Wurapa, Anson, Baumgarten, Axel, Berhe, Mezgebe, Pozniak, Anton, Orkin, Chloe, Tiraboschi, Juan Manuel, Hagins, Debbie P, Huang, Hailin, Andreatta, Kristin, Unger, Nathan, Hindman, Jason, Martin, Hal, Baeten, Jared, Osiyemi, Olayemi
Publicado 2022

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80

por Kumar, Princy N, Goldstein, Deborah A, Hengel, Richard L, Gaur, Aditya H, Wurapa, Anson K, Khalsa, Ann M, Newman, Cheryl L, Saunders, Gary, Liu, Shan-Yu, Dvory-Sobol, Hadas, Rhee, Martin, Gupta, Samir K
Publicado 2023

1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV

por Hagins, Debbie, Kumar, Princy, Saag, Michael, Wurapa, Anson K, Brar, Indira, Berger, Daniel, Osiyemi, Olayemi, Hileman, Corrilynn, Ramgopal, Moti, McDonald, Cheryl, Blair, Christiana, Andreatta, Kristen, Collins, Sean E, Brainard, Diana M, Martin, Hal
Publicado 2020

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

por Hagins, Debbie, Kumar, Princy, Saag, Michael, Wurapa, Anson K., Brar, Indira, Berger, Daniel, Osiyemi, Olayemi, Hileman, Corrilynn O., Ramgopal, Moti N., McDonald, Cheryl, Blair, Christiana, Andreatta, Kristen, Collins, Sean E., Brainard, Diana M., Martin, Hal
Publicado 2021

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

por Rolle, Charlotte-Paige, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson, Ramgopal, Moti, Leone, Peter A., Matthews, Jessica E., Dalessandro, Marybeth, Underwood, Mark R., Angelis, Konstantinos, Wynne, Brian R., Merrill, Deanna, Nguyen, Christopher, van Wyk, Jean, Zolopa, Andrew R.
Publicado 2021

75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Stu...

por Rolle, Charlotte-Paige M, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson K, Ramgopal, Moti, Jayaweera, Dushyantha, Leone, Peter, Matthews, Jessica, Cupo, Michael, Underwood, Mark, Angelis, Kostas, Wynne, Brian, Merrill, Deanna, Nguyen, Christopher T, van Wyk, Jean A, Zolopa, Andrew
Publicado 2021

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

por Rolle, Charlotte-Paige, Berhe, Mezgebe, Singh, Tulika, Ortiz, Roberto, Wurapa, Anson, Ramgopal, Moti, Jayaweera, Dushyantha T, Leone, Peter A, Matthews, Jessica E, Cupo, Michael, Underwood, Mark R, Angelis, Konstantinos, Wynne, Brian R, Merrill, Deanna, Nguyen, Christopher, van Wyk, Jean, Zolopa, Andrew R
Publicado 2023

2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease...

por Eron, Joseph J, Lelievre, Jean-Daniel, Kalayjian, Robert, Slim, Jihad, Wurapa, Anson K, Stephens, Jeffrey L, McDonald, Cheryl, Cua, Eric, Wilkin, Arjun, McKellar, Mehri, Cox, Stephanie, Majeed, Sophia, Blair, Christiana, Carter, Christoph C, SenGupta, Devi, Brainard, Diana M, Das, Moupali
Publicado 2019